Аннотация:Uncertainties exist about the risk of psoriasis patients being treated by biologics during the COVID-19 pandemic.Some data point to an increased risk of respiratory infections in patients being treated with antagonists of interleukin (IL)-17 and tumor necrosis factor-alpha (TNFα) [1,2].On the other hand, these same drugs have been used to treat the sometimes deadly 'cytokine storm' of 4].In this study, we evaluated the incidence of COVID-19 in a population of patients with plaque psoriasis receiving biologic therapies compared with the general population.All patients were observed at the out-patient clinics of three Dermatology Units uniformly covering the Veneto region in Italy, namely Verona, Padua and Vicenza.General statistics and data on comorbidities in the underlying regional population were retrieved from ISTAT census data [8] and the Italian Observatory on Healthcare Report 2018 [9].Data on COVID-19 confirmed cases, including demographics, hospitalizations and deaths, were extracted from the Regional Health Agency [10] as well as from the National Health Institute (ISS) [11].From February 20 to June 1, 2020, a total of 1830 patients were included in the main analysis, with a total of 6199.5 patient-months of follow-up.The characteristics of the studied population are outlined in Table 1.Most of them (55.3%) were treated with TNF *
